Vaccines to prevent systemic mycoses: Holy grails meet translational realities

Journal of Infectious Diseases

Volumn 197, Issue 7, 2008, Pages 938-940

  Galgiani, John N ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; COCCIDIOIDAL VACCINE; FLAGELLIN; FORMALIN KILLED WHOLE CELL VACCINE; FREUND ADJUVANT; LIPID; MONOPHOSPHORYL LIPID; POLIOMYELITIS VACCINE; RECOMBINANT PROTEIN ALS3; RECOMBINANT VACCINE; VACCINE;

CANDIDEMIA; CANDIDIASIS; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; POLIOMYELITIS; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY CONTROL; UNSPECIFIED SIDE EFFECT;

ADJUVANTS, IMMUNOLOGIC; FUNGAL VACCINES; HUMANS; MYCOSES;

EID: 42549118630     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/529205     Document Type: Editorial

References (28)

1. Spellberg B, Ibrahim AS, Lin L, et al. Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity. J Infect Dis 2007; 197:967-71 (in this issue).
2. Cutler JE, Deepe GS Jr, Klein BS. Advances in combating fungal diseases: vaccines on the threshold. Nat Rev Microbiol 2007; 5:13-28.
3. Dan JM, Levitz SM. Prospects for development of vaccines against fungal diseases. Drug Resist Updat 2006; 9:105-10.
4. Datta K, Pirofski LA. Towards a vaccine for Cryptococcus neoformans: principles and caveats. FEMS Yeast Res 2006; 6:525-36.
5. Casadevall A, Pirofski LA. Feasibility and prospects for a vaccine to prevent cryptococcosis. Med Mycol 2005; 43:667-80.
6. Deepe GS Jr, Wuthrich M, Klein BS. Progress in vaccination for histoplasmosis and blastomycosis: coping with cellular immunity. Med Mycol 2005; 43:381-9.
7. Feldmesser M. Prospects of vaccines for invasive aspergillosis. Med Mycol 2005; 43:571-87.
8. Cole GT, Xue JM, Okeke CN, et al. A vaccine against coccidioidomycosis is justified and attainable. Med Mycol 2004; 42:189-216.
9. Deepe GS, Jr. Preventative and therapeutic vaccines for fungal infections: from concept to implementation. Expert Rev Vaccines 2004; 3:701-9.
10. Salkin D, Said A. Reinfection with coccidioidomycosis. Clin Infect Dis 1993; 17:1066.
11. Levine HB, Cobb JM, Smith CE. Immunity to coccidioidomycosis induced in mice by purified spherule, arthrospore, and mycelial vaccines. Trans N Y Acad Sci 1960; 22:436-47.
12. Pappagianis D, Levine HB. The present status of vaccination against coccidioidomycosis in man. Am J Epidemiol 1975; 102:30-41.
13. Pappagianis D, Valley Fever Vaccine Study Group. Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. Am Rev Respir Dis 1993; 148:656-60.
14. Hector R, Rutherford GW. The public health need and present status of a vaccine for the prevention of coccidioidomycosis. Ann N Y Acad Sci 2007; 1111:259-68.
15. Orsborn KI, Shubitz LF, Peng T, et al. Protein expression profiling of Coccidioides posadasii by two-dimensional differential in-gel electrophoresis and evaluation of a newly recognized peroxisomal matrix protein as a recombinant vaccine candidate. Infect Immun 2006; 74:1865-72.
16. Tarcha EJ, Basrur V, Hung CY, Gardner MJ, Cole GT. Multivalent recombinant protein vaccine against coccidioidomycosis. Infect Immun 2006; 74:5802-13.
17. Tarcha EJ, Basrur V, Hung CY, Gardner MJ, Cole GT. A recombinant aspartyl protease of Coccidioides posadasii induces protection against pulmonary coccidioidomycosis in mice. Infect Immun 2006; 74:516-27.
18. Delgado N, Xue J, Yu JJ, Hung CY, Cole GT. A recombinant beta-1,3-glucanosyltransferase homologof Coccidioides posadasii protects mice against coccidioidomycosis. Infect Immun 2003; 71:3010-9.
19. Ivey FD, Magee DM, Woitaske MD, Johnston SA, Cox RA. Identification of a protective antigen of Coccidioides immitis by expression library immunization. Vaccine 2003; 21:4359-67.
20. Shubitz LF, Yu JJ, Hung CY, et al. Improved protection of mice against lethal respiratory infection with Coccidioides posadasii using two recombinant antigens expressed as a single protein. Vaccine 2006; 24:5904-11.
21. Johnson SM, Lerche NW, Pappagianis D, Yee JL, Galgiani JN, Hector RF. Safety, antigenicity, and efficacy of a recombinant coccidioidomycosis vaccine in cynomolgus macaques (Macaca fascicularis). AnnNY Acad Sci 2007; 1111:290-300.
22. Spellberg BJ, Filler SG, Edwards JE Jr. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006; 42:244-51.
23. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-17.
24. McDonald WF, Huleatt JW, Foellmer HG, et al. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J Infect Dis 2007; 195:1607-17.
25. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42:657-68.
26. Stratton KR, Durch JS, Lawrence RS. Vaccines for the 21st century: a tool for decision making. Washington: Division of Health Promotion and Disease Prevention, Institute of Medicine, 1999.
27. Barnato AE, Sanders GD, Owens DK. Cost-effectiveness of a potential vaccine for Coccidioides immitis. Emerging Infectious Diseases 2001; 7:797-806.
28. Park BJ, Sigel K, Vaz V, et al. An epidemic of coccidioidomycosis in Arizona associated with climatic changes, 1998-2001. J Infect Dis 2005; 191:1981-7.